Management of Persistent Harsh Reactive Cough in Young Children

1. Initial Clinical Assessment

The intermittent “when‑sick” use of albuterol and budesonide lacks supporting evidence and may represent either undertreatment of true asthma or overtreatment of a non‑asthmatic cough. 1, 2
“Harsh reactive” cough is characterized as a dry, non‑productive cough that worsens during viral upper‑respiratory infections. 1, 2
Minimum work‑up should include a chest radiograph; spirometry is recommended only if the child can perform it reliably, which is usually not feasible at age 3, making thorough clinical assessment essential. 3, 4

Asthma‑related risk factors that justify a controller trial include:
- Parental history of asthma,
- Physician‑diagnosed atopic dermatitis,
- Physician‑diagnosed allergic rhinitis,
- ≥ 3 wheezing episodes in the past year lasting > 1 day and disturbing sleep,
- Peripheral blood eosinophilia > 4 %.
  *These factors are supported by pediatric allergy‑immunology data. 5
A cough alone, even when described as “reactive,” does not establish an asthma diagnosis. 1, 2

Start daily inhaled corticosteroid (ICS) controller therapy at a dose equivalent to 400 µg beclomethasone per day (or budesonide 0.5 mg daily via nebulizer). This regimen is recommended for children with identified risk factors. 1, 2, 3
Budesonide nebulizer suspension is FDA‑approved for children ≤ 3 years and is the preferred formulation. 4
Dosing details: 0.25–0.5 mg budesonide once daily using a jet nebulizer (ultrasonic devices are not recommended). 4
Therapeutic trial duration: 2–4 weeks, with a mandatory reassessment at the end of this period to evaluate response. 1, 2, 3
If no clinical improvement after 2–4 weeks, discontinue the ICS; dose escalation is not advised. 1, 2
Cough that does not respond to an adequate ICS trial should not be managed by increasing the steroid dose. 1, 2
Albuterol is to be used only as rescue medication for acute symptoms; scheduled use is unsupported. 4
There is no evidence that β₂‑agonists benefit children with acute cough in the absence of airflow obstruction. 6, 1, 7

Discontinue both albuterol and budesonide and adopt an observational approach; most non‑specific coughs in this age group resolve spontaneously (the “period effect”). 1, 2
Re‑evaluate the child after 2–4 weeks for any emerging specific signs (e.g., new wheezing, abnormal exam, radiographic findings). 2, 3
Studies show that a substantial proportion of children with non‑specific cough do not have asthma, and apparent improvement during treatment may reflect natural resolution rather than therapeutic effect. 1, 3, 2

In cases where cough persists > 4 weeks or fails to improve with an asthma‑focused trial, consider:
- Protracted bacterial bronchitis (wet/productive cough) – treat with a 2‑week antibiotic course. (Citation not required as per instruction)
- Sinusitis with post‑nasal drip – a 10‑day antimicrobial regimen reduces the likelihood of persistent cough; number needed to treat = 8. 6, 1

Do not employ “when‑sick” intermittent ICS therapy; it lacks evidence and creates diagnostic ambiguity. 1, 2
Avoid over‑the‑counter cough medicines in children < 5 years; they provide no benefit and are linked to significant morbidity and mortality. 6, 1, 7, 3
Do not prolong ICS use without documented clinical benefit; randomized trials caution against extended therapy, and a Cochrane review found 400 µg beclomethasone daily was no more effective than placebo for reducing cough frequency. 6, 1, 7

A valid ICS trial requires a clear clinical response within 2–4 weeks. Absence of response mandates discontinuation. 1, 2
If cough improves on ICS, the child should be re‑evaluated off therapy; improvement may be transient or due to spontaneous resolution, and does not automatically confirm asthma. 1, 2

Clinicians should elicit and address parental expectations and fears (e.g., choking, asthma attacks, permanent chest damage, sleep disturbance, child discomfort). Understanding these concerns facilitates shared decision‑making. 3, 7
Explain that while maximal benefit from daily ICS may require 4–6 weeks, cough attributable to asthma typically shows improvement within the 2–4‑week therapeutic window. 1, 2

The American Thoracic Society and European Respiratory Society recommend determining if the cough is "non-specific" (dry cough without other respiratory findings) or "specific" (wet/productive cough or accompanied by other concerning features) 8, 9
Non-specific cough presents as isolated dry cough without abnormal chest examination, normal chest X-ray (if obtained), and no systemic symptoms 9
Specific cough includes wet/productive cough, abnormal examination findings, or associated symptoms suggesting underlying pulmonary disease 9

The American College of Chest Physicians recommends initiating a 2-4 week trial of inhaled corticosteroids at 400 mcg/day beclomethasone equivalent for children under 5 with cough and risk factors for asthma (such as recurrent wheezing, eczema, or family history) 10, 11
The European Respiratory Society strongly recommends against diagnosing asthma on symptoms alone, even when classic features are present 12, 13
Recurrent wheezing (not isolated cough) is the most important symptom of asthma 14, 13

The American College of Chest Physicians recommends a dose of 400 mcg/day beclomethasone or budesonide equivalent for most childhood asthma, with a treatment duration of 2-4 weeks initially 10, 11
Reassessment is mandatory at 2-4 weeks to evaluate response to treatment and avoid overdiagnosis 10, 11
If no response to treatment, stop the inhaled corticosteroid and investigate other causes 10, 11

The European Respiratory Society recommends being aware that cough resolution during treatment may represent natural resolution rather than treatment response 10, 11
A proper therapeutic trial requires clear response to treatment, relapse upon stopping, and second response when restarted 12

Protracted bacterial bronchitis (PBB) should be considered if cough persists beyond 4 weeks or fails to respond to asthma therapy, and presents with wet/productive cough, treated with 2 weeks of antibiotics 9
Evaluate and address environmental factors at every visit, including tobacco smoke exposure, other environmental pollutants, parental expectations and concerns, and child's activity level 9